X

Godavari Drugs Ltd. Stock Analysis

Small Cap
Evaluated by 267 users | BSE: 530317 | NSE: |
Pharmaceuticals & Drugs
Godavari Drugs was incorporated as a private limited company on December 2, 1987 and subsequently converted into a public limited company on September 25, 1992.  It was promoted by Ghanshyam Jaju, Mukund Kakani and PC Shrimal.  The company has set up a project to manufacture 180 TPA...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 0.93%-14.98%6.3%15.24%23.42%10.06%9.92%6.8%8.35%9.09%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 5.23.77.69.454.971.175.664.583.595.7
Y-o-Y Gr. Rt.--29%104.8%23.8%481.7%29.7%6.3%-14.8%29.6%14.6%
Adjusted EPS (Rs.) 0.01-2.120.642.064.581.691.730.811.552.61
Y-o-Y Gr. Rt.--21300%NA221.9%122.3%-63.1%2.4%-53.2%91.4%68.4%
Book Value per Share (Rs.) 12.059.9310.5712.6317.3419.1421.5422.6424.2426.9
Adjusted Net Profit 0-1.60.51.63.51.31.30.61.22
Net Op. Cash Flow (Rs. Cr.) 0.60.50.82.2-5.9-4.55.23.83.76.2
Debt to Cash Flow from Ops 2.264.232.971.08-1.45-3.423.065.025.944.42
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Godavari Drugs Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 38.1%11.8%8.2%14.6%
Adjusted EPS 85.6%-10.6%14.7%68.4%
Book Value per Share 9.39.27.711
Share Price 16.1% -12.8% -1.3% 106.5%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 0.06-19.36.2517.7730.579.268.533.686.610.21
Operating Profit Margin (%) 17.94-15.2720.5219.5410.556.356.966.36.576.31
Net Profit Margin (%) 0.1-42.956.3216.456.291.791.730.951.392.05
Debt to Equity 0.150.280.30.250.651.080.971.121.211.36
Working Capital Days 35966034226098154180249221219
Cash Conversion Cycle 156304117109435860787275
Entity Percentage Holding
Promoters 55.86%
Institutions 0.50%
Non-Institutions 43.65%
Pledged *9.699.699.699.699.699.690.009.699.379.37
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Godavari Drugs's performance infers:

Godavari Drugs earnings have declined by -10.6%, whereas share price has depreciated -12.8% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Godavari Drugs share prices over the last 10 years. Here is what we found out:

Godavari Drugs share price has depreciated 16.5% annually over the past ten years.

Godavari Drugs was incorporated as a private limited company on December 2, 1987 and subsequently converted into a public limited company on September 25, 1992.  It was promoted by Ghanshyam Jaju, Mukund Kakani and PC Shrimal. 

The company has set up a project to manufacture 180 TPA at Sulphamethoxazole (SMX) in 1988. The project is located at Maharashtra Industrial Development Corporation (MIDC), Nanded, a notified class ‘C’ backward district in Maharashtra. The

Godavari Drugs was incorporated as a private limited company on December 2, 1987 and subsequently converted into a public limited company on September 25, 1992.  It was promoted by Ghanshyam Jaju, Mukund Kakani and PC Shrimal. 

The company has set up a project to manufacture 180 TPA at Sulphamethoxazole (SMX) in 1988. The project is located at Maharashtra Industrial Development Corporation (MIDC), Nanded, a notified class ‘C’ backward district in Maharashtra. The project was fully commissioned on July 3, 1989.

The registered office of the company is located at Secunderabad in Andhra Pradesh and Mukund Kakani is its Managing Director.

Business area of the company

The company’s principal activity is to manufacture and sell bulk drugs. It undertakes contract manufacturing from various organizations. The products include Pyrazinamide and Ethambutol HCL.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback